European AIDS Conference: Biotechnology Fighting HIV Threat

23.11.2003

Warsaw - The Polish capital hosted the 9th European AIDS Conference (EACS) from October 25-29. As Europe is moving fast in the fight against HIV, approximately 3,000 visitors at this year's conference venue - the Warsaw International Expo-centre EXPO XXI (see photo) - affirmed the very high interest in this topic. Among the latest results of retroviral therapy and the presentation of the 48 week in treatment-data of F. Hoffmann-La Roche's fusion inhibitor and potential block buster Fuzeon, modern biotechnological approaches were discussed thoroughly. Prof Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland, debated the pros and cons of HIV-vaccines. As companies like Merck, Aventis, GSK, Bavarian Nordic and Acambis are already developing vaccine candidates using different vectors and are conducting pre- and even clinical trials, this new approach in the fight against HIV still has to suffer many setbacks. Early this year the vaccine AIDSVAX by the U.S. company VaxGen Inc. flunked phase III trials. The future of the once promissing drug candidate is still uncertain.

Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...

Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...

Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...

Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...

Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...

Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...

Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...

Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...

Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Free newsletter!

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...